Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1641 | Thyroid (non-cancer) | ICEECE2012

Is Japan an iodine excess country? Current iodine status assessed by urinary iodine and food frequency questionnaire

Fuse Y. , Tanaka T. , Ogawa H. , Fujita M. , Fuse Y. , Yamaguchi S. , Yamaguchi M. , Arata N. , Harada S. , Ohashi T. , Shishiba Y. , Irie M.

Japan has been regarded as a nongoitorous country due to the regular intake of iodine-rich food. However, nationwide information on current status of iodine intake is not available because there is no survey system for iodine nutrition in Japan.Objective: The objectives of this study is to characterize current iodine status in Japan.Methods: Since 2002 we have conducted studies on iodine nutrition in the Metropolitan area including...

ea0029p155 | Bone & Osteoporosis | ICEECE2012

Functional hypoparathyroidism is a risk factor for bone fragility of postmenopausal women with vitamin D insufficiency

Yamauchi M. , Nawata K. , Kaji H. , Takaoka S. , Yamaguchi T. , Sugimoto T.

Aim: Vitamin D insufficiency is associated with an increase in PTH, which might be critical for an increase in bone fragility. However, the role of endogenous PTH in vitamin D insufficiency-induced increase in fracture risk still remains unclear. The present study was performed to examine the relationships among vitamin D insufficiency, bone fragility, PTH and sclerostin, which is produced by osteocytes and inhibits bone formation by inhibiting the Wnt pathway.<p class="ab...

ea0029p453 | Clinical case reports - Thyroid/Others | ICEECE2012

Marked improvement of gastrointestinal pseudo-obstruction after debulking surgery of malignant pheochromocytoma by Intravenous administration of α-blocker phentolamine

Yamaguchi S. , Shibata H. , Miyashita K. , Kurihara I. , Oguchi H. , Futatsuki K. , Murai-Takeda A. , Mitsuishi Y. , Motosugi Y. , Jo R. , Hayashi K. , Itoh H.

We present a case of severe malignant pheochromocytoma complicated with intestinal pseudo-obstruction, which was refractory to conventional therapies but reacted to intravenous administration of an α-blocker, phentolamine.Malignant pheochromocytoma typically metastasizes to bones, liver, lungs, and lymph nodes, and average 5-year survival rate in the patient with metastases is approximately 50%. Treatment options for malignant pheochromocytoma inclu...